CAS NO: | 1467093-03-3 |
包装 | 价格(元) |
10 mM * 1 mL in DMSO | 电议 |
5mg | 电议 |
10mg | 电议 |
25mg | 电议 |
50mg | 电议 |
100mg | 电议 |
200mg | 电议 |
500mg | 电议 |
生物活性 | Adavivint (SM04690; Lorecivivint) is a potent and selective inhibitor of canonicalWntsignaling, with anEC50of 19.5 nM via a high-throughput TCF/LEF-reporter assay in SW480 coloncancercells[1]. | ||||||||||||||||
IC50& Target | EC50: 19.5 nM (Wnt, SW480 cell)[1] | ||||||||||||||||
体外研究 (In Vitro) | Adavivint (SM04690) is a potent and selective inhibitor of Wnt signaling, with an EC50of 19.5 nM via a high-throughput TCF/LEF-reporter assay in SW480 colon cancer cells, and shows no effect on SV40 luciferase reporter. Adavivint enhances aggregation of human mesenchymal stem cells (hMSCs) with an EC50of 10 nM. Adavivint (30 nM) protects chondrocytes from catabolic breakdown in vitro[1]. | ||||||||||||||||
体内研究 (In Vivo) | Adavivint (0.3 μg) enhances cartilage repair and protection in the rat acute cruciate ligament tear and partial medial meniscectomy osteoarthritis (ACLT + pMMx OA) model[1]. | ||||||||||||||||
Clinical Trial | |||||||||||||||||
分子量 | 505.55 | ||||||||||||||||
性状 | Solid | ||||||||||||||||
Formula | C29H24FN7O | ||||||||||||||||
CAS 号 | 1467093-03-3 | ||||||||||||||||
运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||||||||||
储存方式 |
| ||||||||||||||||
溶解性数据 | In Vitro: DMSO : 25 mg/mL(49.45 mM;Need ultrasonic and warming) H2O :< 0.1 mg/mL(insoluble) 配制储备液
* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百
|